Literature DB >> 30081622

Enhanced Permeability and Retention-like Extravasation of Nanoparticles from the Vasculature into Tuberculosis Granulomas in Zebrafish and Mouse Models.

Federico Fenaroli1, Urska Repnik1, Yitian Xu2, Kerstin Johann3, Simon Van Herck4, Pradip Dey5, Frode Miltzov Skjeldal1, Dominik M Frei1, Shahla Bagherifam6, Agnese Kocere1, Rainer Haag5, Bruno G De Geest4, Matthias Barz3, David G Russell2, Gareth Griffiths1.   

Abstract

The enhanced permeability and retention (EPR) effect is the only described mechanism enabling nanoparticles (NPs) flowing in blood to reach tumors by a passive targeting mechanism. Here, using the transparent zebrafish model infected with Mycobacterium marinum we show that an EPR-like process also occurs allowing different types of NPs to extravasate from the vasculature to reach granulomas that assemble during tuberculosis (TB) infection. PEGylated liposomes and other NP types cross endothelial barriers near infection sites within minutes after injection and accumulate close to granulomas. Although ∼100 and 190 nm NPs concentrated most in granulomas, even ∼700 nm liposomes reached these infection sites in significant numbers. We show by confocal microscopy that NPs can concentrate in small aggregates in foci on the luminal side of the endothelium adjacent to the granulomas. These spots are connected to larger foci of NPs on the ablumenal side of these blood vessels. EM analysis suggests that NPs cross the endothelium via the paracellular route. PEGylated NPs also accumulated efficiently in granulomas in a mouse model of TB infection with Mycobacterium tuberculosis, arguing that the zebrafish embryo model can be used to predict NP behavior in mammalian hosts. In earlier studies we and others showed that uptake of NPs by macrophages that are attracted to infection foci is one pathway for NPs to reach TB granulomas. This study reveals that when NPs are designed to avoid macrophage uptake, they can also efficiently target granulomas via an alternative mechanism that resembles EPR.

Entities:  

Keywords:  EPR; mouse; mycobacteria; nanoparticles; tuberculosis; zebrafish

Mesh:

Year:  2018        PMID: 30081622     DOI: 10.1021/acsnano.8b04433

Source DB:  PubMed          Journal:  ACS Nano        ISSN: 1936-0851            Impact factor:   15.881


  15 in total

1.  Recent Developments in Drug Delivery for Treatment of Tuberculosis by Targeting Macrophages.

Authors:  Anirudh Gairola; Aaron Benjamin; Joshua D Weatherston; Jeffrey D Cirillo; Hung-Jen Wu
Journal:  Adv Ther (Weinh)       Date:  2022-03-09

2.  In vitro Evaluation of Isoniazid Derivatives as Potential Agents Against Drug-Resistant Tuberculosis.

Authors:  Joaquim Trigo Marquês; Catarina Frazão De Faria; Marina Reis; Diana Machado; Susana Santos; Maria da Soledade Santos; Miguel Viveiros; Filomena Martins; Rodrigo F M De Almeida
Journal:  Front Pharmacol       Date:  2022-05-04       Impact factor: 5.988

3.  Enhancing Antimicrobial Peptide Potency through Multivalent Presentation on Coiled-Coil Nanofibrils.

Authors:  Chaitanya Kumar Thota; Dorian J Mikolajczak; Christian Roth; Beate Koksch
Journal:  ACS Med Chem Lett       Date:  2020-12-14       Impact factor: 4.345

4.  Low-dose X-ray enhanced tumor accumulation of theranostic nanoparticles for high-performance bimodal imaging-guided photothermal therapy.

Authors:  Qiaolin Wei; Jian He; Shuaifei Wang; Shiyuan Hua; Yuchen Qi; Fangyuan Li; Daishun Ling; Min Zhou
Journal:  J Nanobiotechnology       Date:  2021-05-26       Impact factor: 10.435

5.  In Vivo Optofluidic Switch for Controlling Blood Microflow.

Authors:  Xiaoshuai Liu; Qing Gao; Yao Zhang; Yuchao Li; Baojun Li
Journal:  Adv Sci (Weinh)       Date:  2020-06-09       Impact factor: 16.806

6.  Real-time imaging of polymersome nanoparticles in zebrafish embryos engrafted with melanoma cancer cells: Localization, toxicity and treatment analysis.

Authors:  Agnese Kocere; Julien Resseguier; Jens Wohlmann; Frode Miltzow Skjeldal; Shanawaz Khan; Martin Speth; Nils-Jørgen Knudsen Dal; Matthew Yoke Wui Ng; Noelia Alonso-Rodriguez; Edoardo Scarpa; Loris Rizzello; Giuseppe Battaglia; Gareth Griffiths; Federico Fenaroli
Journal:  EBioMedicine       Date:  2020-07-21       Impact factor: 8.143

7.  Monitoring drug nanocarriers in human blood by near-infrared fluorescence correlation spectroscopy.

Authors:  Inka Negwer; Andreas Best; Meike Schinnerer; Olga Schäfer; Leon Capeloa; Manfred Wagner; Manfred Schmidt; Volker Mailänder; Mark Helm; Matthias Barz; Hans-Jürgen Butt; Kaloian Koynov
Journal:  Nat Commun       Date:  2018-12-13       Impact factor: 14.919

8.  Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis.

Authors:  Arnaud Machelart; Giuseppina Salzano; Xue Li; Aurore Demars; Anne-Sophie Debrie; Mario Menendez-Miranda; Elisabetta Pancani; Samuel Jouny; Eik Hoffmann; Nathalie Deboosere; Imène Belhaouane; Carine Rouanet; Sophie Simar; Smaïl Talahari; Valerie Giannini; Baptiste Villemagne; Marion Flipo; Roland Brosch; Fabrice Nesslany; Benoit Deprez; Eric Muraille; Camille Locht; Alain R Baulard; Nicolas Willand; Laleh Majlessi; Ruxandra Gref; Priscille Brodin
Journal:  ACS Nano       Date:  2019-03-08       Impact factor: 15.881

9.  89Zr-Labeled Multifunctional Liposomes Conjugate Chitosan for PET-Trackable Triple-Negative Breast Cancer Stem Cell Targeted Therapy.

Authors:  Rui Yang; Mudan Lu; Lan Ming; Yu Chen; Kai Cheng; Jie Zhou; Shiwen Jiang; Zhenyu Lin; Daozhen Chen
Journal:  Int J Nanomedicine       Date:  2020-11-17

10.  Trans-Cyclooctene-Functionalized PeptoBrushes with Improved Reaction Kinetics of the Tetrazine Ligation for Pretargeted Nuclear Imaging.

Authors:  E Johanna L Stéen; Jesper T Jørgensen; Kerstin Johann; Kamilla Nørregaard; Barbara Sohr; Dennis Svatunek; Alexander Birke; Vladimir Shalgunov; Patricia E Edem; Raffaella Rossin; Christine Seidl; Friederike Schmid; Marc S Robillard; Jesper L Kristensen; Hannes Mikula; Matthias Barz; Andreas Kjær; Matthias M Herth
Journal:  ACS Nano       Date:  2020-01-02       Impact factor: 15.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.